Clinical Trial

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-11-27; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2024-03-20
Trial Details
NCT Number NCT06150664
Lead Sponsor Compass Therapeutics
Conditions Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Enrollment 85 participants
Start Date 2024-03-19
Primary Completion 2026-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-28